Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,698.79
(
-0.26%
)
US TECH 100
24,048.00
(
-0.35%
)
Dow Jones
46,814.19
(
-0.38%
)
Brent Oil
105.38
(
4.69%
)
Bitcoin
72,498.44
(
-1.95%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 143897

Thursday, 06/14/2012 3:37:42 PM

Thursday, June 14, 2012 3:37:42 PM

Post# of 257253
Whether or not such a formulation patent issues and gets included in the Orange Book, I doubt that thrice-weekly Copaxone will attract generic competition unless/until it proves to be a commercial success. I don’t expect NVS/MNTA to file an ANDA for this product.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now